Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.
CSPG4
canine melanoma
comparative oncology
immunotherapy
vaccination
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
10
2021
accepted:
10
01
2022
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
1
3
2022
Statut:
epublish
Résumé
In veterinary oncology, canine melanoma is still a fatal disease for which innovative and long-lasting curative treatments are urgently required. Considering the similarities between canine and human melanoma and the clinical revolution that immunotherapy has instigated in the treatment of human melanoma patients, special attention must be paid to advancements in tumor immunology research in the veterinary field. Herein, we aim to discuss the most relevant knowledge on the immune landscape of canine melanoma and the most promising immunotherapeutic approaches under investigation. Particular attention will be dedicated to anti-cancer vaccination, and, especially, to the encouraging clinical results that we have obtained with DNA vaccines directed against chondroitin sulfate proteoglycan 4 (CSPG4), which is an appealing tumor-associated antigen with a key oncogenic role in both canine and human melanoma. In parallel with advances in therapeutic options, progress in the identification of easily accessible biomarkers to improve the diagnosis and the prognosis of melanoma should be sought, with circulating small extracellular vesicles emerging as strategically relevant players. Translational advances in melanoma management, whether achieved in the human or veterinary fields, may drive improvements with mutual clinical benefits for both human and canine patients; this is where the strength of comparative oncology lies.
Identifiants
pubmed: 35224082
doi: 10.3389/fvets.2022.803093
pmc: PMC8873926
doi:
Types de publication
Journal Article
Langues
eng
Pagination
803093Subventions
Organisme : NIDCR NIH HHS
ID : R01 DE028172
Pays : United States
Informations de copyright
Copyright © 2022 Tarone, Giacobino, Camerino, Ferrone, Buracco, Cavallo and Riccardo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Vet Diagn Invest. 2010 May;22(3):438-41
pubmed: 20453222
Vet Comp Oncol. 2021 Dec;19(4):651-660
pubmed: 33751759
J Am Vet Med Assoc. 2014 Aug 15;245(4):401-7
pubmed: 25075823
J Invest Dermatol. 2016 May;136(5):994-1001
pubmed: 26829031
Oncoimmunology. 2012 May 1;1(3):316-325
pubmed: 22737607
Front Pharmacol. 2020 Apr 07;11:441
pubmed: 32317979
Oncoimmunology. 2019 Apr 3;8(7):1593806
pubmed: 31143514
Vet Immunol Immunopathol. 2014 Jan 15;157(1-2):31-41
pubmed: 24268690
Vet Sci. 2019 Feb 12;6(1):
pubmed: 30759787
Pharmaceuticals (Basel). 2020 Aug 04;13(8):
pubmed: 32759810
J Immunol. 2002 Jun 15;168(12):6294-7
pubmed: 12055244
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33158916
Hum Pathol. 2016 Aug;54:157-64
pubmed: 27107457
NPJ Precis Oncol. 2021 Feb 12;5(1):10
pubmed: 33580183
Curr Top Microbiol Immunol. 2017;405:55-78
pubmed: 25682101
Expert Opin Biol Ther. 2014 Oct;14(10):1427-42
pubmed: 25023219
Sci Rep. 2018 Oct 24;8(1):15732
pubmed: 30356111
Melanoma Res. 2017 Dec;27(6):596-600
pubmed: 29016387
Vet Clin North Am Small Anim Pract. 2019 Sep;49(5):xiii-xiv
pubmed: 31345517
J Cell Physiol. 1998 Nov;177(2):299-312
pubmed: 9766527
Immunol Rev. 2020 Jul;296(1):169-190
pubmed: 32594569
Nat Commun. 2019 Nov 8;10(1):5108
pubmed: 31704921
Cancers (Basel). 2011 Aug 10;3(3):3225-41
pubmed: 24212954
Int J Mol Sci. 2020 Jul 17;21(14):
pubmed: 32709086
Am J Vet Res. 2011 Dec;72(12):1631-8
pubmed: 22126691
J Extracell Vesicles. 2020 Jan 7;9(1):1710899
pubmed: 32002173
Nat Rev Cancer. 2021 Jun;21(6):360-378
pubmed: 33907315
Pigment Cell Melanoma Res. 2011 Dec;24(6):1148-57
pubmed: 22004131
Clin Cancer Res. 2003 Apr;9(4):1284-90
pubmed: 12684396
Nat Commun. 2019 Jan 21;10(1):353
pubmed: 30664638
Vet Immunol Immunopathol. 2021 Feb;232:110169
pubmed: 33387703
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):6-16
pubmed: 32335187
Front Oncol. 2019 Jan 15;8:680
pubmed: 30697532
J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):188-97
pubmed: 7834118
HNO. 2020 Feb;68(2):100-105
pubmed: 32006045
Vet Comp Oncol. 2018 Jun;16(2):276-287
pubmed: 29271043
Gynecol Oncol. 2014 Jan;132(1):203-10
pubmed: 24216048
J Hematol Oncol. 2021 Jan 29;14(1):21
pubmed: 33514401
Expert Rev Mol Diagn. 2018 Dec;18(12):1029-1040
pubmed: 30406709
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Vet Immunol Immunopathol. 2007 Mar 15;116(1-2):69-78
pubmed: 17224188
Chemotherapy. 2019;64(2):62-80
pubmed: 31387102
Vet Comp Oncol. 2013 Sep;11(3):219-29
pubmed: 23909996
Front Vet Sci. 2021 Aug 16;8:707025
pubmed: 34485435
Vet Immunol Immunopathol. 2006 Dec 15;114(3-4):273-84
pubmed: 17027091
Int J Cancer. 1981 Sep 15;28(3):293-300
pubmed: 7033148
MAbs. 2021 Jan-Dec;13(1):2004638
pubmed: 34856888
Oncogene. 2008 Sep 4;27(39):5182-94
pubmed: 18469852
BMC Vet Res. 2020 Nov 18;16(1):447
pubmed: 33208160
Cancer Immunol Immunother. 2011 Dec;60(12):1729-38
pubmed: 21779876
Nature. 2005 Dec 8;438(7069):803-19
pubmed: 16341006
Sci Rep. 2017 Aug 21;7(1):8951
pubmed: 28827658
Front Immunol. 2018 Feb 05;9:133
pubmed: 29459862
Cancer Immunol Immunother. 2019 Nov;68(11):1839-1853
pubmed: 31222484
Cancer Res. 2012 Mar 1;72(5):1070-80
pubmed: 22266112
Curr Top Microbiol Immunol. 2017;405:99-122
pubmed: 25294003
Sci Rep. 2020 Oct 27;10(1):18311
pubmed: 33110170
Theranostics. 2015 Feb 15;5(5):530-44
pubmed: 25767619
Endocr Relat Cancer. 2017 Dec;24(12):T261-T281
pubmed: 28893836
Vet Comp Oncol. 2021 Jun;19(2):353-361
pubmed: 33443307
Int J Mol Sci. 2018 Mar 10;19(3):
pubmed: 29534457
Int J Exp Pathol. 2006 Jun;87(3):163-76
pubmed: 16709225
J Transl Med. 2017 Jul 1;15(1):151
pubmed: 28668095
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
ESMO Open. 2020 Feb;5(1):
pubmed: 32392177
Cancer Immunol Immunother. 2006 Apr;55(4):433-42
pubmed: 15965647
Ann Oncol. 2021 Apr;32(4):466-477
pubmed: 33548389
Genes (Basel). 2019 Jun 30;10(7):
pubmed: 31262050
Vet Pathol. 2021 May;58(3):491-502
pubmed: 33764216
Blood. 2015 May 21;125(21):3335-46
pubmed: 25814530
Cancer Immunol Immunother. 2015 Feb;64(2):137-48
pubmed: 25548094
J Vet Intern Med. 2010 Nov-Dec;24(6):1439-44
pubmed: 20840314
Vet Pathol. 2021 May;58(3):453-471
pubmed: 33813952
Cancer Res. 2016 May 15;76(10):2921-31
pubmed: 27020860
Clin Cancer Res. 2014 Jul 15;20(14):3753-62
pubmed: 24874834
PLoS Genet. 2018 Sep 6;14(9):e1007589
pubmed: 30188888
Angew Chem Int Ed Engl. 2021 Nov 2;60(45):24179-24188
pubmed: 34469031
PLoS One. 2011;6(9):e24751
pubmed: 21931843
Clin Cancer Res. 2012 Oct 1;18(19):5352-63
pubmed: 22893632
J Transl Med. 2018 Dec 11;16(1):349
pubmed: 30537967
Int J Mol Sci. 2018 Jan 30;19(2):
pubmed: 29385676
J Mol Evol. 1993 Mar;36(3):290-300
pubmed: 8483166
Medicine (Baltimore). 2018 Jul;97(30):e11446
pubmed: 30045267
ESMO Open. 2020 Mar;4(Suppl 3):e000629
pubmed: 32152062
Front Oncol. 2019 Nov 05;9:1148
pubmed: 31750245
Annu Rev Anim Biosci. 2016;4:199-222
pubmed: 26566160
J Hematol Oncol. 2021 Mar 19;14(1):45
pubmed: 33741032
Histopathology. 2014 Nov;65(5):726-8
pubmed: 24750176
Adv Cancer Res. 2010;109:73-121
pubmed: 21070915
Animals (Basel). 2019 Aug 19;9(8):
pubmed: 31430895
PLoS One. 2021 Aug 12;16(8):e0255798
pubmed: 34383787
J Am Vet Med Assoc. 2011 Feb 15;238(4):480-5
pubmed: 21320018
J Cell Biol. 2004 Jun 21;165(6):881-91
pubmed: 15210734
Curr Opin Investig Drugs. 2003 Jun;4(6):710-5
pubmed: 12901230
Cancer Gene Ther. 2012 Dec;19(12):852-61
pubmed: 23059870
Pharmaceuticals (Basel). 2020 Dec 18;13(12):
pubmed: 33353043
Vaccines (Basel). 2020 Oct 17;8(4):
pubmed: 33080888
Vet J. 2011 Nov;190(2):e26-e30
pubmed: 21482159
Vet Comp Oncol. 2017 Dec;15(4):1333-1345
pubmed: 27723224
Clin Cancer Res. 2021 Mar 1;27(5):1227-1235
pubmed: 33051306
Methods Enzymol. 1996;266:460-80
pubmed: 8743700
Medicine (Baltimore). 2018 Jul;97(30):e11648
pubmed: 30045314
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Oncol Lett. 2020 Nov;20(5):176
pubmed: 32934743
Ther Adv Med Oncol. 2019 Jun 06;11:1758835919855491
pubmed: 31217827
J Nanobiotechnology. 2021 Aug 21;19(1):250
pubmed: 34419056
Cancer Immunol Immunother. 2018 Oct;67(10):1533-1544
pubmed: 30051333
Monoclon Antib Immunodiagn Immunother. 2013 Dec;32(6):395-8
pubmed: 24328742
Clin Dev Immunol. 2010;2010:683875
pubmed: 21127709
Front Oncol. 2018 Jul 06;8:264
pubmed: 30035102
Vet Comp Oncol. 2020 Sep;18(3):370-380
pubmed: 31750993
Clin Dev Immunol. 2011;2011:842849
pubmed: 22190973
J Clin Invest. 1998 Jun 1;101(11):2406-14
pubmed: 9616212
J Vet Intern Med. 2005 Jan-Feb;19(1):56-63
pubmed: 15715049
Front Immunol. 2020 Jan 17;10:2935
pubmed: 32010120
J Exp Clin Cancer Res. 2019 Apr 5;38(1):146
pubmed: 30953535
Pigment Cell Melanoma Res. 2017 Sep;30(5):467-476
pubmed: 28513992
Clin Cancer Res. 2004 Jul 15;10(14):4717-23
pubmed: 15269144
Expert Opin Biol Ther. 2021 May;21(5):587-602
pubmed: 33301369
Vet Sci. 2016 Feb 19;3(1):
pubmed: 29056717
Vaccine. 2004 Jul 29;22(21-22):2904-9
pubmed: 15246627
Cancers (Basel). 2019 Jan 24;11(2):
pubmed: 30682795
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):986-97
pubmed: 24661650
Front Vet Sci. 2021 Jul 23;8:695222
pubmed: 34368282
Mol Cancer Ther. 2020 Nov;19(11):2308-2318
pubmed: 32943547
Vet Comp Oncol. 2017 Sep;15(3):996-1013
pubmed: 27146852
Mol Cancer. 2020 Jul 17;19(1):116
pubmed: 32680511
Int J Cancer. 2016 Oct 1;139(7):1618-25
pubmed: 27252119
Nat Immunol. 2003 Sep;4(9):899-906
pubmed: 12925852
Int J Mol Sci. 2017 Mar 17;18(3):
pubmed: 28304339
Lab Invest. 2019 Jul;99(8):1117-1129
pubmed: 30914782